Drug Trial Radar · NCT07736937
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Mar 30, 2026
Primary completion
Mar 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer. This study will also evaluate the appropriate dose of TUB-040 when used with carboplatin (Carbo) and bevacizumab (BEV), including determining the maximum tolerated dose (MTD) in participants with platinum-sensitive ovarian cancer.
Conditions
- Ovarian Cancer
Interventions
TUB-040 + Carbo + BEVDrug
Ph1b: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered along with carboplatin (Carbo) and bevacizumab (BEV) as an intravenous (IV) solution on day 1 of each treatment cycle for up to 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the safety and tolerability of TUB-040 in combination with standard ovarian cancer drugsTime frame: From enrollment until 30 days after last study drug
- Maximum Tolerated Dose (MTD) of TUB-040 with standard of care (SOC) treatmentTime frame: Day 1 up to Day 21 of each treatment cycle
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Start Cal
Los Angeles, California · Recruiting
Start Njeb
East Brunswick, New Jersey · Recruiting
Start Nyli
New York, New York · Recruiting
UCL Louvain
Brussels, Belgium · Recruiting
UZ Gent
Ghent, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
CHU de Liege
Liège, Belgium · Recruiting
ARENSIA Exploratory Medicine
Kyiv, Ukraine · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.